two significant new approaches for treating and preventing breast cancer
October 1998
The FDA is close to approving two significant new approaches for treating and preventing breast cancer.
Herceptin (trastuzumab) will be a major breakthrough...it's the first monoclonal antibody for treating metastatic breast cancer.
It targets HER2...a protein that stimulates the growth of breast cancer cells. About 30% of women with breast cancer have tumors that produce excessive amounts of HER2.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote